rs-93427-007 and Arteriosclerosis

RS-93427 is a potent, orally active prostacyclin-mimetic that is very rapidly absorbed but with generally long-lived actions in most species. It has antithrombotic, thrombolytic, and antivasospastic potential. Alone among several tested PGI-mimetics, it inhibits release of platelet mitogens more potently than its ability to inhibit aggregation. It also inhibits mitogen release from macrophages and vascular endothelial cells. RS-93427 is also potent at inhibiting macrophage accumulation of cholesteryl esters. These data suggest a broad spectrum of potential therapeutic utility for RS-93427 via the oral route. It might be useful both in acute manifestations of vascular occlusive disease involving thrombosis and vasospasm, in addition to the more chronic conditions involving intimal hyperplasia (as in arteriovenous grafts) and possibly frank atherosclerosis. Much work remains to be done, including examination of RS-93427 in chronic studies with various dosage forms, particularly in the study of atherosclerosis.

Topics: Administration, Oral; Animals; Arterial Occlusive Diseases; Arteriosclerosis; Biological Availability; Bridged-Ring Compounds; Fibrinolysis; Humans; In Vitro Techniques; Platelet Aggregation; Thrombosis; Vasodilation

Topics: Administration, Oral; Arteriosclerosis; Blood Platelets; Bridged-Ring Compounds; Epoprostenol; Humans; Muscle, Smooth, Vascular; Prostaglandins, Synthetic